What we’re reading, January 5, 2017: Vice President Joe Biden will create a nonprofit organization to focus on cancer research and drug prices; school telemedicine could help kids stay in the classroom and out of the doctor’s office; bundled payments for joint replacements saved $5577 in spending per episode.
After 2 terms as vice president and endeavors like the Cancer Moonshot Initiative and the 21st Century Cures Act, Joe Biden does not plan to rest when he leaves office this month. In an interview with The Washington Post, Biden announced he would create a new nonprofit, tentatively called the Biden Cancer Initiative, to encourage oncology research. He also said that another major focus would be lowering the price of cancer drugs, especially for underserved populations.
According to a Pew report, telemedicine in schools could be a “game changer” for children’s health, allowing them to stay in the classroom longer by reducing unnecessary trips to a physician’s office or even the emergency room. Advocates predict that more school districts will use virtual medicine for managing chronic conditions or providing mental health counseling, not just addressing acute health complaints. However, a major barrier to implementation is the lack of coverage; just 18 states authorize Medicaid reimbursement for school telemedicine.
A JAMA investigation found a cost savings of $5577 per joint replacement episode when using the Medicare bundled payment model. The major drivers of the savings were reductions in implant costs and lower post-acute spending, including inpatient rehabilitation and skilled nursing facility costs. Readmissions and emergency department visits declined slightly, and episodes with a prolonged length of stay decreased 67%.
Current and Emerging Options for Uncommon EGFR- and Exon 20 Insertion–Mutated NSCLC
September 8th 2025Uncommon EGFR mutations in non–small cell lung cancer (NSCLC) remain challenging to treat, but new tyrosine kinase inhibitors, bispecific antibodies, and a proposed “PACCage insert” framework provide opportunities to advance precision therapy.
Read More
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Evolving Roles of Antibody-Drug Conjugates in the Treatment of NSCLC
September 7th 2025Antibody-drug conjugates are rapidly reshaping the treatment landscape of non–small cell lung cancer (NSCLC), with advances in design, clinical efficacy, and regulatory approvals tempered by ongoing challenges in toxicity, resistance, and biomarker optimization.
Read More
From Amivantamab to Next-Generation Therapies: The Evolving Bispecific Antibody Landscape in NSCLC
September 6th 2025Bispecific antibodies are emerging as a transformative class in advanced non–small cell lung cancer (NSCLC), with agents such as amivantamab and zenocutuzumab already demonstrating clinical benefit and a broad pipeline of investigational therapies showing promise in overcoming resistance.
Read More